Information Provided By:
Fly News Breaks for December 14, 2017
ARQL
Dec 14, 2017 | 08:49 EDT
As reported earlier, Needham analyst Chad Messer upgraded ArQule to Buy from Hold with a $5 price target. Messer says the recent developments - miransertib trials for Proteus syndrome, Phase Ia/b data for the BTK-inhibitor ARQ531, and interim pivotal data for derazantn - make this the appropriate time to "step up and buy shares" ahead of a "potentially transformative 2018".
News For ARQL From the Last 2 Days
There are no results for your query ARQL
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.